KG&L Capital Management LLC Purchases 18,029 Shares of Pfizer Inc. (NYSE:PFE)

KG&L Capital Management LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 49.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,702 shares of the biopharmaceutical company’s stock after purchasing an additional 18,029 shares during the period. Pfizer comprises 1.8% of KG&L Capital Management LLC’s holdings, making the stock its 11th largest position. KG&L Capital Management LLC’s holdings in Pfizer were worth $1,965,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Morgan Stanley boosted its stake in shares of Pfizer by 2.4% during the 2nd quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock worth $2,015,972,000 after buying an additional 1,071,897 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Pfizer by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock worth $1,911,852,000 after buying an additional 1,559,405 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after buying an additional 34,544,423 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 2.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock worth $1,557,306,000 after buying an additional 868,839 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Pfizer by 5.3% during the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock worth $1,004,428,000 after buying an additional 1,159,857 shares during the last quarter. Hedge funds and other institutional investors own 71.69% of the company’s stock.

NYSE:PFE traded up $0.32 during mid-day trading on Friday, hitting $36.11. The stock had a trading volume of 17,478,458 shares, compared to its average volume of 19,407,336. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The stock has a market cap of $195.97 billion, a price-to-earnings ratio of 12.04, a PEG ratio of 2.82 and a beta of 0.66. The company’s 50 day simple moving average is $35.94 and its 200 day simple moving average is $39.97. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period last year, the business posted $0.77 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.81 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.99%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

Several equities research analysts recently issued reports on PFE shares. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Goldman Sachs Group reiterated a “buy” rating and issued a $49.00 target price on shares of Pfizer in a research note on Monday, June 17th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research note on Tuesday, October 1st. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a research note on Wednesday, August 28th. Finally, Morgan Stanley cut their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. Twelve investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus target price of $45.20.

In related news, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were bought at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Trading Ex-Dividend

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.